Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 2:19 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 887 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Climara Clear all
Completed Phase 4 Interventional Results available

Effect of Perimenstrual Ovarian Steroid Supplementation on Perimenstrual Suicidality

NCT03720847
View directory record Official record
Conditions
Suicidal Ideation
Interventions
Estradiol Transdermal Patch 0.1 mg/24 hrs, Oral Micronized Progesterone, Inactive Clear Patch, Placebo capsule
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 4, 2019 · Synced Oct 22, 2026, 2:19 AM EDT
Completed Phase 1Phase 2 Interventional

Combination Chemotherapy in Treating Patients With Advanced Cancer

NCT00004105
View directory record Official record
Conditions
Leukemia, Lymphoma, Sarcoma, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
estramustine phosphate sodium, paclitaxel, vinorelbine ditartrate
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 28, 2011 · Synced Oct 22, 2026, 2:19 AM EDT
Completed Phase 3 Interventional

SPIRIT 2: Efficacy and Safety Study of Relugolix in Women With Endometriosis-Associated Pain

NCT03204331
View directory record Official record
Conditions
Endometriosis Related Pain
Interventions
Relugolix, Estradiol/norethindrone acetate, Estradiol/norethindrone acetate placebo, Relugolix placebo
Drug
Lead sponsor
Myovant Sciences GmbH
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
623 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
41
States / cities
Andalusia, Alabama • Washington D.C., District of Columbia • Aventura, Florida + 36 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2021 · Synced Oct 22, 2026, 2:19 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

The Interaction Between Diabetes and Estradiol on Human Brain Metabolism in Postmenopausal Women

NCT03681691
View directory record Official record
Conditions
Diabetes Type 2, Dementia
Interventions
Estradiol patch
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
60 Years to 80 Years · Female only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 27, 2022 · Synced Oct 22, 2026, 2:19 AM EDT
Terminated Phase 2 Interventional

High-Dose Esterified Estrogens in Treating Postmenopausal Women With Metastatic Breast Cancer That Has Failed Previous Hormone Therapy

NCT00131924
View directory record Official record
Conditions
Breast Cancer
Interventions
esterified estrogens
Biological
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 11, 2012 · Synced Oct 22, 2026, 2:19 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

AG200-15 Transdermal Contraceptive Delivery System (TCDS) of Levonorgestrel and Ethinyl Estradiol

NCT01243580
View directory record Official record
Conditions
Healthy
Interventions
Ortho-Cyclen, AG200-15
Drug
Lead sponsor
Agile Therapeutics
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 22, 2026, 2:19 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Brain Blood Flow Responses to Stress: Sex Differences

NCT06253702
View directory record Official record
Conditions
Cerebrovascular Disorders
Interventions
Indomethacin, Placebo, Orilissa, Testosterone gel, Anastrozole, Estradiol
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 40 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 22, 2026, 2:19 AM EDT
Completed Early Phase 1 Interventional

Mediators of Abnormal Reproductive Function in Obesity (MARO)

NCT01817400
View directory record Official record
Conditions
Infertility, Female, Obesity
Interventions
Microdialysis, Vascepa - Fish Oil, Aspirin, Pioglitazone
Other · Dietary Supplement · Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 17, 2015 · Synced Oct 22, 2026, 2:19 AM EDT
Recruiting Phase 1 Interventional

Reversing InGuinal Hernia Trial: The Evaluation of Sex Hormones to Reverse Inguinal Hernias in Males

NCT07604272
View directory record Official record
Conditions
Inguinal Hernia Unilateral, Inguinal Hernia Bilateral, Inguinal Hernia Without Obstruction or Gangrene, Inguinal Hernia, Without Mention of Obstruction or Gangrene
Interventions
Fulvestrant, Anastrozole (ARIMIDEX™)
Drug
Lead sponsor
Northwestern University
Other
Eligibility
50 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 22, 2026, 2:19 AM EDT
Withdrawn Phase 2 Interventional

Phase 2 Study of Fulvestrant With and Without Entinostat in Postmenopausal Women With ER+ Advanced Breast Cancer

NCT02115594
View directory record Official record
Conditions
Breast Cancer
Interventions
Fulvestrant, Entinostat, Placebo
Drug
Lead sponsor
Syndax Pharmaceuticals
Industry
Eligibility
Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 8, 2014 · Synced Oct 22, 2026, 2:19 AM EDT
Completed Phase 2 Interventional Results available

Pilot Study of the Effect of Duavee® on Benign Breast Tissue Proliferation

NCT02729701
View directory record Official record
Conditions
Breast Cancer
Interventions
Duavee
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
Up to 61 Years · Female only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
2
States / cities
Kansas City, Kansas • Westwood, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 9, 2022 · Synced Oct 22, 2026, 2:19 AM EDT
Recruiting Not applicable Interventional

Satavari and Ashoka for Menopause (SAM) Study

NCT07861295
View directory record Official record
Conditions
Menopause
Interventions
Ashoka Bark and Shatavari, Placebo
Dietary Supplement · Other
Lead sponsor
Vidya USA Corporation
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
New Port Richey, Florida
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 22, 2026, 2:19 AM EDT
Recruiting Phase 1 Interventional

Estradiol Plus Olaparib for Breast Cancer (PHOEBE)

NCT05900895
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Olaparib, 17b-estradiol
Drug
Lead sponsor
Mary D Chamberlin
Other
Eligibility
18 Years and older · Female only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Nov 20, 2025 · Synced Oct 22, 2026, 2:19 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Buccal Estrogen in Toothpaste Study: Systemic Absorption of Estradiol When Administered Mixed With Toothpaste in Postmenopausal or Surgically Menopausal Women

NCT00029757
View directory record Official record
Conditions
Menopause, Postmenopause
Interventions
Estrogen
Drug
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
35 Years to 75 Years · Female only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 7, 2005 · Synced Oct 22, 2026, 2:19 AM EDT
Recruiting Phase 2 Interventional

Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score

NCT02476786
View directory record Official record
Conditions
Breast Cancer, Cancer of Breast, Breast Neoplasms, Cancer of the Breast
Interventions
FACT-B, Goserelin, Anastrozole, Exemestane, Fulvestrant, Tamoxifen, Archived tissue collection
Behavioral · Drug · Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
70 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2032
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 22, 2026, 2:19 AM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Study in Women on the Effect of JNJ-64530440 on Oral Contraceptive and Midazolam, and the Effect of a High-fat Meal on JNJ-64530440

NCT03890341
View directory record Official record
Conditions
Healthy
Interventions
Drospirenone/Ethinylestradiol, Midazolam, JNJ-64530440
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 26, 2021 · Synced Oct 22, 2026, 2:19 AM EDT
Recruiting Phase 1Phase 2 Interventional

Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors

NCT07287917
View directory record Official record
Conditions
Melanoma (Skin Cancer), HER2-low Hormone Receptor Positive Breast Cancer
Interventions
AMXT 1501 Dicaprate, DFMO, Fulvestrant, Capivasertib, Pembrolizumab
Drug
Lead sponsor
Aminex Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
20
States / cities
Tucson, Arizona • La Jolla, California • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 22, 2026, 2:19 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Effect of GSK3640254 on the Pharmacokinetics of a Combination Oral Contraceptive

NCT03984825
View directory record Official record
Conditions
HIV Infections
Interventions
GSK3640254, Portia
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 27, 2020 · Synced Oct 22, 2026, 2:19 AM EDT
Completed Phase 1 Interventional

A Study of LY3023414 in Participants With Advanced Cancer

NCT01655225
View directory record Official record
Conditions
Advanced Cancer, Metastatic Cancer, Non-Hodgkin's Lymphoma, Metastatic Breast Cancer, Malignant Mesothelioma, Non-small Cell Lung Cancer
Interventions
LY3023414, Midazolam, Fulvestrant, Pemetrexed, Cisplatin, Abemaciclib, Letrozole
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2022
U.S. locations
6
States / cities
Los Angeles, California • New York, New York • Oklahoma City, Oklahoma + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2022 · Synced Oct 22, 2026, 2:19 AM EDT
Active, not recruiting Phase 2 Interventional

The Role of Estrogen in the Neurobiology of Eating Disorders

NCT03740204
View directory record Official record
Conditions
Eating Disorders, Hypoestrogenemia
Interventions
17-β estradiol transdermal patches with cyclic progesterone, Placebo patch and pill
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
14 Years to 35 Years · Female only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 22, 2026, 2:19 AM EDT
Recruiting Phase 1Phase 2 Interventional

ORION-1: Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid Tumors

NCT06998407
View directory record Official record
Conditions
HR+/HER2- Breast Cancer, HR+, HER2-, Advanced Breast Cancer
Interventions
AVZO-021, Fulvestrant, Letrozole, AVZO-023
Drug
Lead sponsor
Avenzo Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
16
States / cities
Los Angeles, California • New Haven, Connecticut • Orlando, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 22, 2026, 2:19 AM EDT
Terminated Phase 2 Interventional Results available

Binge Eating & Birth Control

NCT04278755
View directory record Official record
Conditions
Bulimia Nervosa, Binge Eating, Eating Disorders, Binge-Eating Disorder
Interventions
Drospirenone-Ethinyl Estradiol Oral Tablet
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 34 Years · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 26, 2022 · Synced Oct 22, 2026, 2:19 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Cardiometabolic Consequences of the Loss of Ovarian Function

NCT06264882
View directory record Official record
Conditions
Menopause, Estrogen Deficiency, Aging, Adiposity
Interventions
Degarelix, Transdermal Estradiol Patch, Transdermal Placebo Patch
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
20 Years to 45 Years · Female only
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 20, 2024 · Synced Oct 22, 2026, 2:19 AM EDT
Completed Phase 2 Interventional Results available

Phase 2a Study of ZW25 in Combination With Palbociclib Plus Fulvestrant

NCT04224272
View directory record Official record
Conditions
HER2+/HR+ Breast Cancer
Interventions
ZW25 (Zanidatamab), Palbociclib, Fulvestrant
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
3
States / cities
Santa Monica, California • Nashville, Tennessee • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 22, 2026, 2:19 AM EDT